NLRP3 and Alzheimer disease: We evaluated the expression and secretion of IL-33 in MC903-induced AD model, in which MCC950, a specific inhibitor of NLRP3 inflammasome activation and ASC oligomerization [30, 31], and VX-765, a selective inhibitor of caspase-1 activity [32] were applied (Fig. 3A).